Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate + atomoxetine
- Development stage
- Unknown
- Lead developer
- McNEIL-PPC
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The drug entry 'methylphenidate extended-release + atomoxetine' refers to the comparative evaluation of two distinct ADHD medications, Concerta (methylphenidate HCl extended-release) and Strattera (atomoxetine), as studied in the Phase 4 FOCUS (Formal Observation of Concerta versUs Strattera) trial. Methylphenidate is a small-molecule central nervous system stimulant that acts as a dopamine and norepinephrine reuptake inhibitor (DNRI), utilizing the OROS osmotic release system for once-daily dosing. Atomoxetine is a small-molecule, non-stimulant selective norepinephrine reuptake inhibitor (NRI). Both drugs are FDA-approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. The FOCUS study (NCT00866996) was a randomized, open-label trial designed to compare treatment outcomes as evaluated by physicians and parents in a community setting.
- Brand names
- ConcertaStrattera
- Other names
- methylphenidate extended-release + atomoxetine
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate + atomoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate + atomoxetine.